logo-loader
viewDestiny Pharma PLC

Destiny Pharma: 'Opportunities for quality assets that deliver solutions for infection prevention'

Destiny Pharma PLC 's (LON:DEST) chief executive Neil Clark talks to Proactive London's Polly Middlehurst about the company's focus on developing new anti-infectives for the prevention of infections. 

Clark also discusses the government-funded COVID-19 product navel spray, part of a collaboration agreement with UK biotech SporeGen, to co-develop SporeGen's SPOR-COV product as a novel, preventive treatment. 

Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.

Clark says they are "some great opportunities for quality assets that deliver solutions in this whole area of infection prevention".

Quick facts: Destiny Pharma PLC

Price: 122.5 GBX

AIM:DEST
Market: AIM
Market Cap: £73.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Destiny Pharma mark 'exciting time, completing studies and delivering data'

Destiny Pharma PLC's (LON:DEST) Neil Clarke talks to Proactive London's Katie Pilbeam about the XF-73 Phase 2b clinical trial which is now fully recruited.  The plan is to finalise the phase 2 data in the first quarter then move on to phase 3, with discussions already taking place...

1 week, 4 days ago

2 min read